Michael G. Natchus

6.5k citations

69 papers · 2.9k indexed · 2 hit papers · h-index 29

Co-authors: George R. Painter Tomáš Hudlický Richard K. Plemper Alexander A. Kolykhalov G. SINAI‐ZINGDE Neil G. Almstead Yetunde O. Taiwo Gregory R. Bluemling
Topics: Respiratory viral infections research (17 papers)Protease and Inhibitor Mechanisms (13 papers)Peptidase Inhibition and Analysis (12 papers)
Cited by: Infectious Diseases Organic Chemistry Cancer Research
Journals: Science Journal of the American Chemical Society Nature Communications
Partner nations: United States Germany Slovakia

In The Last Decade

Michael G. Natchus

68 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

2019 255 citations Maria L. Agostini, Andrea J. Pruijssers et al. Journal of Virology profile →
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

2019 233 citations Märt Toots, Jeong-Joong Yoon et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Michael G. Natchus

Since Specialization

Citations

This map shows the geographic impact of Michael G. Natchus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael G. Natchus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael G. Natchus more than expected).

Fields of papers citing papers by Michael G. Natchus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael G. Natchus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael G. Natchus. The network helps show where Michael G. Natchus may publish in the future.

Co-authorship network of co-authors of Michael G. Natchus

This figure shows the co-authorship network connecting the top 25 collaborators of Michael G. Natchus. A scholar is included among the top collaborators of Michael G. Natchus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael G. Natchus. Michael G. Natchus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine 2025 ·mBio ·Jonna B. Westover,(unknown),(unknown),Kevin W. Bailey,(unknown),(unknown),(unknown),Alexander A. Kolykhalov,Michael G. Natchus,George R. Painter,Brian B. Gowen	0
2	Influenza A virus resistance to 4’-fluorouridine coincides with viral attenuation in vitro and in vivo 2024 ·PLoS Pathogens ·Carolin M. Lieber,(unknown),Megha Aggarwal,Nicole A. P. Lieberman,(unknown),Jeong-Joong Yoon,Michael G. Natchus,Robert M. Cox,Alexander L. Greninger,Richard K. Plemper	4
3	Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models 2023 ·Nature Communications ·Robert M. Cox,Carolin M. Lieber,Josef D. Wolf,Amir-Hossein Karimi,Nicole A. P. Lieberman,Zachary M. Sticher,Pavitra Roychoudhury,(unknown),(unknown),Michael G. Natchus,George R. Painter,Alexander A. Kolykhalov,Alexander L. Greninger,Richard K. Plemper	18
4	The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection 2022 ·Antiviral Research ·Gregory R. Bluemling,(unknown),Michael G. Natchus,Wendy Painter,Sabue Mulangu,Mark A. Lockwood,Abel De La Rosa,Trevor Brasel,Jason E. Comer,Alexander N. Freiberg,Alexander A. Kolykhalov,George R. Painter	9
5	SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model 2022 ·Nature Communications ·Carolin M. Lieber,Robert M. Cox,Julien Sourimant,Josef D. Wolf,(unknown),Quynh Phung,Manohar Saindane,(unknown),Zachary M. Sticher,(unknown),Michael G. Natchus,George R. Painter,Kaori Sakamoto,Alexander L. Greninger,Richard K. Plemper	33
6	Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19 2021 ·Current Opinion in Virology ·George R. Painter,Michael G. Natchus,Oren J. Cohen,(unknown),Wendy Painter	112
7	Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity 2021 ·PLoS Pathogens ·Robert M. Cox,Julien Sourimant,(unknown),Michael G. Natchus,Richard K. Plemper	12
8	Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase 2020 ·Nature Microbiology ·Robert M. Cox,Julien Sourimant,Märt Toots,Jeong-Joong Yoon,Satoshi Ikegame,(unknown),Ruth Watkinson,Patricia A. Thibault,Negar Makhsous,Michelle J. Lin,(unknown),Zachary M. Sticher,Alexander A. Kolykhalov,Michael G. Natchus,Alexander L. Greninger,Benhur Lee,Richard K. Plemper	22
9	Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epitheliabreakdown → 2019 ·Science Translational Medicine ·Märt Toots,Jeong-Joong Yoon,Robert M. Cox,M. N. Hart,Zachary M. Sticher,Negar Makhsous,Roland Plesker,(unknown),Prabhakar Reddy,Deborah G. Mitchell,Ryan C. Shean,Gregory R. Bluemling,Alexander A. Kolykhalov,Alexander L. Greninger,Michael G. Natchus,George R. Painter,Richard K. Plemper	233
10	The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection 2019 ·Antiviral Research ·George R. Painter,Richard A. Bowen,Gregory R. Bluemling,(unknown),(unknown),(unknown),David B. Guthrie,Michael Hager,(unknown),Mark A. Lockwood,Deborah G. Mitchell,Michael G. Natchus,Zachary M. Sticher,Alexander A. Kolykhalov	81
11	Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistancebreakdown → 2019 ·Journal of Virology ·Maria L. Agostini,Andrea J. Pruijssers,James D. Chappell,Jennifer Gribble,Xiaotao Lu,Erica L. Andres,Gregory R. Bluemling,Mark A. Lockwood,Timothy P. Sheahan,Amy Sims,Michael G. Natchus,Manohar Saindane,Alexander A. Kolykhalov,George R. Painter,Ralph S. Baric,Mark R. Denison	255
12	Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model 2019 ·Translational research ·Märt Toots,Jeong-Joong Yoon,M. N. Hart,Michael G. Natchus,George R. Painter,Richard K. Plemper	85
13	β- d - N ⁴ -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome 2017 ·Journal of Virology ·Nadya Urakova,Valeriya Kuznetsova,David K. Crossman,Arpine Sokratian,David B. Guthrie,Alexander A. Kolykhalov,Mark A. Lockwood,Michael G. Natchus,Michael R. Crowley,George R. Painter,Elena I. Frolova,Ilya Frolov	148
14	Asymmetric synthesis of host-directed inhibitors of myxoviruses 2013 ·Beilstein Journal of Organic Chemistry ·Terry W. Moore,(unknown),Dan Yan,(unknown),John M. Ndungu,Manohar Saindane,Mark A. Lockwood,Michael G. Natchus,Dennis C. Liotta,Richard K. Plemper,James P. Snyder,Aiming Sun	12
15	MSX-122, an orally available small molecule CXCR4 antagonist, promotes leukocytosis in monkeys at doses that were well tolerated in a 28 day toxicology study 2008 ·Cancer Research ·Michael G. Natchus,Richard F. Arrendale,(unknown)	1
16	Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis 2006 ·Inflammation Research ·Michael J. Janusz,(unknown),Kimberly K. Brown,Lily C. Hsieh,S.A. Heitmeyer,Yetunde O. Taiwo,Michael G. Natchus,(unknown),Neil G. Almstead,Bing‐ling Peng,Timothy R. Baker,(unknown)	12
17	The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold 2001 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Matthew J. Laufersweiler,John C. VanRens,Michael G. Natchus,Roger G. Bookland,Neil G. Almstead,Stanisław Pikul,Biswanath De,Lily C. Hsieh,Michael J. Janusz,(unknown),Sean Peng,(unknown),Tomáš Hudlický,(unknown)	17
18	Chemoenzymatic synthesis of functionalized cyclohexylglycines and α-methylcyclohexylglycines via Kazmaier–Claisen rearrangement 2001 ·Bioorganic & Medicinal Chemistry Letters ·Tomáš Hudlický,(unknown),(unknown),(unknown),Matthew J. Laufersweiler,Michael G. Natchus	7
19	The Next Generation of MMP Inhibitors: Design and Synthesis 1999 ·Annals of the New York Academy of Sciences ·Biswanath De,Michael G. Natchus,(unknown),Stanisław Pikul,Neil G. Almstead,Yetunde O. Taiwo,Catherine E. Snider,(unknown),(unknown),Fei Gu,Martin E. Dowty	28
20	Design and synthesis of conformationally-constrained MMP inhibitors 1998 ·Bioorganic & Medicinal Chemistry Letters ·Michael G. Natchus,(unknown),(unknown),Stanisław Pikul,Neil G. Almstead,(unknown),Yetunde O. Taiwo,Glen E. Mieling,C. Michelle Dunaway,Catherine E. Snider,(unknown),B.L. Barnett,(unknown),(unknown),Biswanath De	26

About Michael G. Natchus

Michael G. Natchus is a scholar working on Infectious Diseases, Cancer Research and Oncology, having authored 69 papers that have together received 2.9k indexed citations. Recurring topics across this work include Respiratory viral infections research (17 papers), Protease and Inhibitor Mechanisms (13 papers) and Peptidase Inhibition and Analysis (12 papers). The work is most often cited by research in Infectious Diseases (1.0k citations), Organic Chemistry (744 citations) and Cancer Research (366 citations). Michael G. Natchus has collaborated with scholars based in United States, Germany and Slovakia. Frequent co-authors include George R. Painter, Tomáš Hudlický, Richard K. Plemper, Alexander A. Kolykhalov, G. SINAI‐ZINGDE, Neil G. Almstead, Yetunde O. Taiwo, Gregory R. Bluemling, Jeong-Joong Yoon and Biswanath De. Their work appears in journals such as Science, Journal of the American Chemical Society and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact